BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

361 related articles for article (PubMed ID: 26195705)

  • 1. Use of Biomarkers to Guide Decisions on Systemic Therapy for Women With Metastatic Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline.
    Van Poznak C; Somerfield MR; Bast RC; Cristofanilli M; Goetz MP; Gonzalez-Angulo AM; Hicks DG; Hill EG; Liu MC; Lucas W; Mayer IA; Mennel RG; Symmans WF; Hayes DF; Harris LN
    J Clin Oncol; 2015 Aug; 33(24):2695-704. PubMed ID: 26195705
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline.
    Harris LN; Ismaila N; McShane LM; Andre F; Collyar DE; Gonzalez-Angulo AM; Hammond EH; Kuderer NM; Liu MC; Mennel RG; Van Poznak C; Bast RC; Hayes DF;
    J Clin Oncol; 2016 Apr; 34(10):1134-50. PubMed ID: 26858339
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Recommendations on disease management for patients with advanced human epidermal growth factor receptor 2-positive breast cancer and brain metastases: American Society of Clinical Oncology clinical practice guideline.
    Ramakrishna N; Temin S; Chandarlapaty S; Crews JR; Davidson NE; Esteva FJ; Giordano SH; Gonzalez-Angulo AM; Kirshner JJ; Krop I; Levinson J; Modi S; Patt DA; Perez EA; Perlmutter J; Winer EP; Lin NU
    J Clin Oncol; 2014 Jul; 32(19):2100-8. PubMed ID: 24799487
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Focused Update.
    Krop I; Ismaila N; Andre F; Bast RC; Barlow W; Collyar DE; Hammond ME; Kuderer NM; Liu MC; Mennel RG; Van Poznak C; Wolff AC; Stearns V
    J Clin Oncol; 2017 Aug; 35(24):2838-2847. PubMed ID: 28692382
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Receptor discordance rate and its effects on survival in primary and recurrent breast cancer patients.
    Ilgun S; Sarsenov D; Erdogan Z; Ordu C; Celebi F; Nur Pilanci K; Ozturk A; Selamoglu D; Alco G; Aktepe F; Eralp Y; Tuzlali S; Ozmen V
    J BUON; 2016; 21(6):1425-1432. PubMed ID: 28039703
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biomarker discordance: prospective and retrospective evidence that biopsy of recurrent disease is of clinical utility.
    Moussa O; Purdie C; Vinnicombe S; Thompson AM
    Cancer Biomark; 2012-2013; 12(6):231-9. PubMed ID: 23735943
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlation of Expression of Breast Biomarkers in Primary and Metastatic Breast Carcinomas: A Single-Institution Experience.
    Hou Y; Shen R; Chaudhary S; Gao F; Li Z
    Acta Cytol; 2016; 60(5):481-489. PubMed ID: 27681712
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical practice guidelines for the use of tumor markers in breast and colorectal cancer. Adopted on May 17, 1996 by the American Society of Clinical Oncology.
    J Clin Oncol; 1996 Oct; 14(10):2843-77. PubMed ID: 8874347
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The impact of HER2 phenotype of circulating tumor cells in metastatic breast cancer: a retrospective study in 107 patients.
    Wallwiener M; Hartkopf AD; Riethdorf S; Nees J; Sprick MR; Schönfisch B; Taran FA; Heil J; Sohn C; Pantel K; Trumpp A; Schneeweiss A
    BMC Cancer; 2015 May; 15():403. PubMed ID: 25972110
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Estrogen, progesterone, and HER2/neu receptor discordance between primary and metastatic breast tumours-a review.
    Yeung C; Hilton J; Clemons M; Mazzarello S; Hutton B; Haggar F; Addison CL; Kuchuk I; Zhu X; Gelmon K; Arnaout A
    Cancer Metastasis Rev; 2016 Sep; 35(3):427-37. PubMed ID: 27405651
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Metastatic breast carcinoma in pleural fluid: Correlation of receptor and HER2 status with the primary carcinoma-a pilot study.
    Francis IM; Alath P; George SS; Jaragh M; Al Jassar A; Kapila K
    Diagn Cytopathol; 2016 Dec; 44(12):980-986. PubMed ID: 27666130
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hormone Receptor Status and HER2 Expression in Primary Breast Cancer Compared With Synchronous Axillary Metastases or Recurrent Metastatic Disease.
    Rossi S; Basso M; Strippoli A; Dadduzio V; Cerchiaro E; Barile R; D'Argento E; Cassano A; Schinzari G; Barone C
    Clin Breast Cancer; 2015 Oct; 15(5):307-12. PubMed ID: 25922284
    [TBL] [Abstract][Full Text] [Related]  

  • 13. American Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancer. American Society of Clinical Oncology Bisphosphonates Expert Panel.
    Hillner BE; Ingle JN; Berenson JR; Janjan NA; Albain KS; Lipton A; Yee G; Biermann JS; Chlebowski RT; Pfister DG
    J Clin Oncol; 2000 Mar; 18(6):1378-91. PubMed ID: 10715310
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Immunohistochemical hormonal mismatch and human epidermal growth factor type 2 [HER2] phenotype of brain metastases in breast cancer carcinoma compared to primary tumors].
    Joubert C; Boissonneau S; Fina F; Figarella-Branger D; Ouafik L; Fuentes S; Dufour H; Gonçalves A; Charaffe-Jauffret E; Metellus P
    Neurochirurgie; 2016 Jun; 62(3):151-6. PubMed ID: 27236733
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biopsy confirmation of metastatic sites in breast cancer patients: clinical impact and future perspectives.
    Criscitiello C; André F; Thompson AM; De Laurentiis M; Esposito A; Gelao L; Fumagalli L; Locatelli M; Minchella I; Orsi F; Goldhirsch A; Curigliano G
    Breast Cancer Res; 2014; 16(2):205. PubMed ID: 25032257
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Organotropism and prognostic marker discordance in distant metastases of breast carcinoma: fact or fiction? A clinicopathologic analysis.
    St Romain P; Madan R; Tawfik OW; Damjanov I; Fan F
    Hum Pathol; 2012 Mar; 43(3):398-404. PubMed ID: 21840040
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tissue confirmation of disease recurrence in breast cancer patients: pooled analysis of multi-centre, multi-disciplinary prospective studies.
    Amir E; Clemons M; Purdie CA; Miller N; Quinlan P; Geddie W; Coleman RE; Freedman OC; Jordan LB; Thompson AM
    Cancer Treat Rev; 2012 Oct; 38(6):708-14. PubMed ID: 22178456
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the expression of prognostic biomarkers between primary tumor and axillary lymph node metastases in breast cancer.
    Zhao S; Xu L; Liu W; Lv C; Zhang K; Gao H; Wang J; Ma R
    Int J Clin Exp Pathol; 2015; 8(5):5744-8. PubMed ID: 26191291
    [TBL] [Abstract][Full Text] [Related]  

  • 19. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer.
    Harris L; Fritsche H; Mennel R; Norton L; Ravdin P; Taube S; Somerfield MR; Hayes DF; Bast RC;
    J Clin Oncol; 2007 Nov; 25(33):5287-312. PubMed ID: 17954709
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recommendations on Disease Management for Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases: ASCO Clinical Practice Guideline Update.
    Ramakrishna N; Temin S; Chandarlapaty S; Crews JR; Davidson NE; Esteva FJ; Giordano SH; Kirshner JJ; Krop IE; Levinson J; Modi S; Patt DA; Perlmutter J; Winer EP; Lin NU
    J Clin Oncol; 2018 Sep; 36(27):2804-2807. PubMed ID: 29939840
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.